Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, lower back pain and sore feet, dizziness and blurred vision, thirst, dry tongue and sore throat, and heel pain, as well as rheumatic pain, joint pain, generalized pain, wind-cold-dampness arthralgia, gout, neuralgia, be… Read more
Tien Liang BioTech Co., Ltd. (4127) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.021x
Based on the latest financial reports, Tien Liang BioTech Co., Ltd. (4127) has a cash flow conversion efficiency ratio of 0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$10.20 Million) by net assets (NT$478.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tien Liang BioTech Co., Ltd. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Tien Liang BioTech Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tien Liang BioTech Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tien Liang BioTech Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Nordic Metals Corp
OTCQB:FNMCF
|
-0.335x |
|
Y-S Electronic Co Ltd
TWO:6418
|
-0.026x |
|
Great Elm Group Inc
NASDAQ:GEG
|
-0.032x |
|
YeaRimDang Publishing Co. Ltd
KQ:036000
|
0.001x |
|
Arogo Capital Acquisition Corp
NASDAQ:AOGO
|
-0.004x |
|
First Bancshares Inc. (Bellevue OH)
PINK:FIBH
|
0.005x |
|
Groupe CRIT SA
PA:CEN
|
0.031x |
|
Medipharm Labs Corp
OTCQX:MEDIF
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Tien Liang BioTech Co., Ltd. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Tien Liang BioTech Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$477.92 Million | NT$48.34 Million | 0.101x | -28.43% |
| 2023-12-31 | NT$492.98 Million | NT$69.67 Million | 0.141x | +206.88% |
| 2022-12-31 | NT$475.12 Million | NT$21.88 Million | 0.046x | -57.82% |
| 2021-12-31 | NT$414.05 Million | NT$45.21 Million | 0.109x | +470.51% |
| 2020-12-31 | NT$367.25 Million | NT$-10.82 Million | -0.029x | -- |